07:00 , Sep 15, 2014 |  BC Week In Review  |  Financial News

Fennec Pharmaceuticals financial update

Fennec Pharmaceuticals Inc. (TSX:FRX; OTCQB:ADHXD), Research Triangle Park, N.C.   Business: Cancer, Other   Date announced: 2014-09-03   Note: Adherex Technologies Inc. changed its name to Fennec, implemented a 1-for-3 reverse stock split and changed...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Clinical News

Sodium thiosulfate: Phase III data

Preliminary data from 104 evaluable patients ages 1-18 years old receiving cisplatin for newly diagnosed cancer in the open-label, international Phase III ACCL0431 trial showed that 16 g/m 2 IV STS given after each cisplatin...
07:00 , Jun 9, 2014 |  BioCentury  |  Finance

Liberating Labrys

Less than two years after pumping $31 million into migraine play Labrys Biologics Inc. , investors will see a front-loaded return in a takeout by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA). Teva is acquiring Labrys for...
08:00 , Nov 25, 2013 |  BC Week In Review  |  Financial News

Adherex completes private placement of units

Adherex Technologies Inc. (TSX:AHX; OTCQB:ADHXF), Research Triangle Park, N.C.   Business: Cancer, Drug delivery   Date completed: 11/15/13   Type: Private placement of units   Raised: $1.6 million   Units: 4 million   Price: $0.40...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Adherex management update

Adherex Technologies Inc. (TSX:AHX; OTCQB:ADHXF), Research Triangle Park, N.C.   Business: Cancer, Drug delivery   Transitioned: Krysia Lynes to interim CFO; she replaces Robert Andrade, who resigned as CFO and a director  ...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Adherex board of directors update

Adherex Technologies Inc. (TSX:AHX; OTCQB:ADHXF), Research Triangle Park, N.C.   Business: Cancer, Drug delivery   Transitioned: CEO Rostislav Raykov to chairman from a director; he succeeds David Lieberman, who resigned  ...
07:00 , Mar 11, 2013 |  BioCentury  |  Regulation

Dissecting Kadcyla

Two and a half years after FDA refused to file Genentech Inc. 's BLA for accelerated approval of Kadcyla ado-trastuzumab emtansine in metastatic breast cancer, the agency has granted full approval - and outlined its...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Clinical News

Eniluracil: Completed Phase II enrollment

Adherex completed enrollment of 153 patients in the open-label, international Phase II AHX-03-202 trial comparing 40 mg oral eniluracil weekly for the first 3 weeks of a 4-week cycle plus oral 5-fluorouracil (5-FU) and oral...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Financial News

Adherex financial update

Adherex said it regained compliance with requirements for continued listing on the Toronto Stock Exchange. Adherex Technologies Inc. (TSX:AHX; OTCQB:ADHXF), Durham, N.C.   Business: Cancer, Drug delivery   Date announced: 1/6/13  ...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

4Q Stock Wrap-Up: Go big or go home

Large cap biotechs were the only market cap segment to end 4Q12 in the black, finishing up 1% to post a 26% gain on the year. Small caps brought up the rear in 4Q, but...